KRRO

Korro Bio's stock experienced significant volatility. In November 2025, the stock declined sharply due to the failure of KRRO-110, accompanied by workforce reductions and a pause in the Novo Nordisk partnership. In March 2026, a PIPE financing and at-the-market share sales increased cash reserves, extending the cash runway into the second half of 2028. In May 2026, several analyst firms upgraded the stock rating based on positive preclinical data and first-quarter results, leading to a rebound in the stock price year-to-date.